Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

This article will focus on the relationship between serum levels of anti-citrullinated peptide antibodies (anti-CCP) or rheumatoid factor (RF) and clinical response to TNF-α blockers in order to evaluate whether these antibodies may have a role as serological markers of response to therapy in rheumatoid arthritis (RA). The changes induced in anti-CCP levels after TNF blocking therapy still remain a controversial issue even though a marked reduction following conventional DMARDs has been reported in early disease.On the other hand, a drop in RF levels during treatment has been reported by many authors. Decreased IgM RF levels seem to parallel clinical response suggesting that this antibody can also be regarded as a marker of response to treatment. Pre-treatment RF positivity or negativity does not influence response to TNF-α blocking therapy while high pre-treatment levels of IgA RF seem to be associated with a poor response rate.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages287-295
Number of pages9
Volume1109
DOIs
Publication statusPublished - Aug 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1109
ISSN (Print)00778923
ISSN (Electronic)17496632

Keywords

  • Anti-cyclic citrullinated peptide antibodies
  • Rheumatoid arthritis
  • Rheumatoid factor
  • Tumor necrosis factor-α inhibitors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients'. Together they form a unique fingerprint.

Cite this